Davita Inc vs FTAI Aviation Ltd — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while FTAI Aviation Ltd trades at $169.8 (market cap $17.57B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and FTAI Aviation Ltd for 23 Days on average.
| DVA | FTAI | |
|---|---|---|
Market Cap | $11.29B | $17.57B |
Volume | 582,204 | 1,905,014 |
Sector | Health | Industrials |
52-Week High | $240.96 | $310.04 |
52-Week Low | $103.87 | $152.80 |
Typical Hold Time | 114 Days | 23 Days |
Enterprise Value | $24.01B | $20.69B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
FTAI Aviation trades at $169.47, down 3.07% today, with a bearish technical signal from moving averages. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS expectations. Recent developments include a $500M share buyback program and a strategic acquisition of 27 Boeing aircraft, signaling growth focus. Analyst consensus remains unanimously bullish with a $321.25 price target, highlighting institutional confidence despite near-term earnings volatility.
The outlook for FTAI is positive based on robust analyst support and strategic expansions, but risks include consecutive EPS misses and a high P/E ratio of 37.35. Investors face volatility from operational cash flow challenges and competitive pressures in the aviation sector, though the buyback and new partnerships provide catalysts for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →